tracken
Genfit SA Sponsored ADR Aktie News
Neutral
GlobeNewsWire
●
2 Tage alt
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update.
Neutral
GlobeNewsWire
●
2 Tage alt
GENFIT announces the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec
Neutral
GlobeNewsWire
●
12 Tage alt
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Failure (ACLF) research via exosome-based regenerat...
Neutral
GlobeNewsWire
●
12 Tage alt
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a n...
Neutral
GlobeNewsWire
●
23 Tage alt
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it has given formal notice to the Nasdaq Stock Market of the Company's intention to voluntarily delist its American Depositar...
Neutral
GlobeNewsWire
●
25 Tage alt
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Wash...
Neutral
GlobeNewsWire
●
2 Monate alt
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 22, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2025 financial results and provided a corporate update.
Neutral
Seeking Alpha
●
2 Monate alt
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
